/

UTHR

United Therapeutics CorporationPre-market

550.10+0.94 +0.17%USD

NasdaqGS · as of Oct 12, 16:00 ET · 15m delay

Open

553.49

Prev close

549.16

Day range

547.76555.59

52-week range

409.07609.35

Volume

840.63K1.23×

Mkt cap

23.59B

P/E ttm

19.72

Fwd P/E

16.28

EPS ttm

27.89

Div yield

0.00%

Earnings

Aug 5, 2026

From 52w high

−9.72%

Price Chart

Yahoo Finance · delayed

UTHROct 12, 2026O 553.49H 555.59L 547.76C 550.10+0.94 (+0.17%)Vol 840.60K

SMA 50513.24
SMA 200526.32

1Y change +25.02% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

UTHR United Therapeutics Corporation · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: +2.55%
1 month: +10.66%
3 months: +2.71%
6 months: −4.77%
Year to date: +12.90%
1 year: +25.02%

Valuation & ownership

Market cap: 23.59B
Enterprise value: 20.93B
P/E (ttm): 19.72
Forward P/E: 16.28
PEG ratio: 2.22
Price / book: 3.67
Price / sales (ttm): 7.48
EV / EBITDA: 13.99
EPS (ttm): 27.89
EPS (forward): 33.79
Beta (5y monthly): 0.49
Dividend yield: 0.00%
Payout ratio: 0.00%
Shares outstanding: 42.89M
Float: 39.20M
Short % of float: 9.79%
Short ratio (days): 4.18
Held by insiders: 2.00%
Held by institutions: 100.05%
Avg volume (3m): 685.41K
50-day average: 513.24
200-day average: 526.32
52-week change: +25.02%
S&P 500 52-week: +17.50%

Technicals (daily)

RSI (14): 60.4
vs 50-day SMA: +7.18%
vs 200-day SMA: +4.52%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▲ above
ATR (14) % of price: 3.52%
Realised vol (20d, ann.): 55.4%
From 52-week high: −9.72%
From 52-week low: +34.48%

ANR

Analyst Consensus

14 analysts

Consensus

Buy

1.87 on a 1 (strong buy) – 5 (sell) scale

Mean target

651.86

+18.50% implied

Low 321.00Median 692.50High 728.00

Recommendation trend

Now11 / 3 / 1
1m ago

DES

About United Therapeutics Corporation

Yahoo Finance profile

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Employees

SEAS

Seasonality · UTHR

2007–2026 · monthly returns

Strongest month Nov +5.17%Weakest month Mar −2.13%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-3.6	7.3	17.7	-3.6	-2.5	-2.7	-4.5	-1.4	6.2	1.5			+12.9%
2025	-0.5	-8.9	-3.7	-1.7	5.2	-9.9	-4.4	10.9	37.6	6.3	9.1	0.3	+38.1%
2024	-2.3	5.1	1.8	2.0	17.4	15.8	-1.7	16.0	-1.4	4.4	-0.9	-4.8	+60.5%
2023	-5.4	-6.5	-9.0	2.8	-8.9	5.2	10.0	-7.6	0.7	-1.3	7.7	-8.4	−20.9%
2022	-6.6	-17.7	7.9	-1.0	29.7	2.3	-1.9	-1.9	-7.6	10.1	21.4	-0.6	+28.7%
2021	7.9	2.1	0.1	20.5	-7.8	-3.5	1.4	18.1	-14.1	3.3	-0.7	14.0	+42.4%
2020	10.9	5.4	-7.9	15.5	7.7	2.6	-7.9	-4.0	-5.6	32.9	-1.2	14.4	+72.3%
2019	5.9	9.5	-7.1	-12.6	-18.1	-7.0	1.5	4.2	-3.4	12.7	2.7	-4.5	−19.1%
2018	-12.8	-10.2	-3.0	-2.0	-3.2	6.2	8.6	0.1	4.0	-13.3	6.5	-7.8	−26.4%
2017	14.1	-9.7	-8.4	-7.2	-3.8	7.3	-1.0	1.9	-10.4	1.2	9.6	13.8	+3.2%
2016	-21.3	-1.0	-8.6	-5.6	13.2	-11.0	14.2	1.0	-3.4	1.7	4.6	14.2	−8.4%
2015	9.0	9.9	11.2	-7.4	15.0	-5.3	-2.6	-11.1	-12.9	11.7	4.1	2.6	+20.9%
2014	-9.3	-1.2	-7.3	6.4	-4.3	-7.6	2.8	29.6	9.2	1.8	1.2	-2.3	+14.5%
2013	0.9	11.0	1.8	9.7	-0.4	-1.0	13.8	-5.4	11.2	12.3	4.3	22.5	+111.7%
2012	4.1	-2.9	-1.3	-7.2	1.1	11.6	10.9	-1.2	3.3	-18.3	15.1	1.7	+13.1%
2011	7.5	-0.8	-0.6	-0.1	-3.6	-14.7	4.1	-24.8	-13.1	16.6	-6.4	15.5	−25.3%
2010	13.1	-3.6	-3.6	2.8	-10.0	-4.7	0.2	-5.5	21.2	7.1	4.9	0.5	+20.1%
2009	8.6	-1.2	-1.5	-5.0	27.3	4.3	11.1	-1.2	7.1	-13.2	7.2	15.5	+68.3%
2008	-14.0	0.2	3.0	-2.5	13.0	2.3	16.0	-6.4	-0.9	-17.1	-37.1	14.1	−35.9%
2007	-1.4	4.9	-4.3	4.0	18.0	-3.4	8.8	-1.3	-2.8	2.9	46.2	-2.4	+79.6%

INSD

Insider Activity · UTHR

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

161

1.45M shares

Sells, 6 months

156

1.44M shares

Net shares

+16.2K

Net change in insider shares

+1.90%

Date	Insider	Transaction	Shares	Value
Oct 6, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 542.73 - 556.48 per share.	9.5K	$5.22M
Oct 6, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Oct 5, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 527.90 - 545.50 per share.	9.5K	$5.12M
Oct 5, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Oct 4, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 536.26 - 546.63 per share.	9.5K	$5.15M
Oct 4, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Oct 1, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 542.06 - 574.22 per share.	9.5K	$5.22M
Oct 1, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Sep 30, 2026	Mahon Paul AGeneral Counsel	Sale at price 558.30 - 573.15 per share.	8.3K	$4.69M
Sep 30, 2026	Mahon Paul AGeneral Counsel	Conversion of Exercise of derivative security at price 146.03 per share.	8.3K	$1.21M
Sep 29, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 476.14 - 546.23 per share.	7.6K	$3.93M
Sep 29, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Sep 29, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 547.29 - 554.70 per share.	1.9K	$1.06M
Sep 28, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 472.05 - 486.77 per share.	9.5K	$4.54M
Sep 28, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Sep 27, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 472.43 - 486.00 per share.	9.5K	$4.57M
Sep 27, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Sep 24, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 470.56 - 478.95 per share.	9.5K	$4.52M
Sep 24, 2026	Rothblatt Martine AChief Executive Officer	Conversion of Exercise of derivative security at price 117.76 per share.	9.5K	$1.12M
Sep 22, 2026	Rothblatt Martine AChief Executive Officer	Sale at price 488.70 - 500.05 per share.	9.5K	$4.67M

CONG

Congress Trades · UTHR

House and Senate reports since 2025

Members

0 last bought

Buys

~$16.0K

Sells

~$16.0K

Net

+$0

est. bought − sold

Latest

Oct 31, 25

Lisa McClain

Members who traded it

Member	Buys	Sells	Est. net	Last move
Lisa McClain MI09	2	2	+$0	Sold Oct 31, 25

Bought and sold by quarter (est.)

Members of Congress's UTHR trades, newest first
Traded	Member	Owner	Type	Amount	Filed	Report
Oct 31, 25	Lisa McClain MI09	Spouse	Sell	$1,001 - $15,000	Nov 21, 25 (21d)	PDF
Oct 30, 25	Lisa McClain MI09	Spouse	Buy	$1,001 - $15,000	Nov 21, 25 (22d)	PDF
Oct 30, 25	Lisa McClain MI09	Spouse	Sell	$1,001 - $15,000	Nov 21, 25 (22d)	PDF
Jun 11, 25	Lisa McClain MI09	Spouse	Buy	$1,001 - $15,000	Aug 13, 25 (63d)	PDF

From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades

13F

Investors Holding UTHR

latest 13F filings of 29 followed managers

Investors holding UTHR
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$925.8M	1.27%	1.71M	−4.4%	Q2 2026
Bridgewater Associates · Ray Dalio	$60.3M	0.25%	111.33K	—	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

UTHR

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

UTHR

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About United Therapeutics Corporation

Seasonality · UTHR

Insider Activity · UTHR

Congress Trades · UTHR

Members who traded it

Bought and sold by quarter (est.)

Investors Holding UTHR

Investors Holding UTHR

Congress Trades · UTHR

Members who traded it

Bought and sold by quarter (est.)

Insider Activity · UTHR

Seasonality · UTHR

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About United Therapeutics Corporation

Financial Snapshot

Earnings & Dividends

News